Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Active as of 2024-12-19 |
Generated Narrative: Citation 267247
version: 2; Last updated: 2024-11-22 19:28:42+0000
Profile: JournalArticleCitation
url: Citation 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
identifier: FEvIR Object Identifier/https://fevir.net/FOI/267247, https://pubmed.ncbi.nlm.nih.gov
/15832493, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.47
version: 2.0.0-ballot
title: 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
status: Active
date: 2024-12-19 14:29:51+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description:
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
Code | Value[x] |
Citation Classification Type fevir-platform-use: FEvIR Platform Use | Medline Base |
jurisdiction: World
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
approvalDate: 2005-05-18
lastReviewDate: 2019-11-09
author: Computable Publishing®: MEDLINE-to-FEvIR Converter:
classification
type: Citation Source
classifier: MEDLINE
classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section
currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish
statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2005-04-19 09:00:00+0000
statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2005-05-19 09:00:00+0000
statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2005-04-19 09:00:00+0000
citedArtifact
identifier:
https://pubmed.ncbi.nlm.nih.gov
/15832493,https://doi.org
/10.2165/00024677-200201060-00006Titles
Type Language Text Primary title English Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
Abstracts
Text <AbstractText Label="UNLABELLED">Rosiglitazone, a thiazolidinedione with a different side chain from those of troglitazone and pioglitazone, reduces plasma glucose levels and glucose production and increases glucose clearance in patients with type 2 diabetes mellitus. Insulin sensitivity, pancreatic beta-cell function and surrogate markers of cardiovascular risk factors are significantly improved by rosiglitazone. Double-blind trials of 8 to 26 weeks of rosiglitazone 4 or 8 mg/day monotherapy indicate significant decreases in fasting plasma glucose (-2 to -3 mmol/L with 8 mg/day) and glycosylated hemoglobin levels [HbA(1c); -0.6 to -0.7% (-0.8 to -1.1% in drug-naive patients) with 8 mg/day]. Significant decreases in hyperglycemic markers occurred when rosiglitazone was combined with metformin (HbA(1c) -0.8 to -1.0%), a sulfonylurea (-1.4%) or insulin (-1.2%) for 26 weeks versus little change with active comparator monotherapy. Efficacy was maintained in trials of < or =2 years, and was also apparent in various ethnic subgroups, elderly patients and both obese and nonobese patients. Rosiglitazone is currently not indicated in combination with injected insulin. It should be administered in conjunction with diet and exercise regimens. Rosiglitazone is generally well tolerated. Despite rare individual reports of liver function abnormalities in rosiglitazone recipients, the incidence of these in clinical trials (< or =2 years' duration) was similar to that in placebo and active comparator groups. Fluid retention associated with rosiglitazone may be the cause of the increased incidence of anemia in clinical trials, and also means that patients should be monitored for signs of heart failure during therapy. Although bodyweight is increased overall with rosiglitazone therapy, increases are in subcutaneous, not visceral, fat; hepatic fat is decreased. The pharmacokinetic profile of rosiglitazone is not substantially altered by age or renal impairment, nor are there important drug interactions. Rosiglitazone is not indicated in patients with active liver disease or increased liver enzymes. CONCLUSIONS: Oral rosiglitazone 4 or 8 mg/day provides significant antihyperglycemic efficacy and is generally well tolerated, both as monotherapy and in combination with other antihyperglycemic agents, in patients with type 2 diabetes mellitus who do not have active liver disease. Long-term data are required before conclusions can be drawn about the clinical significance of positive changes to surrogate markers of cardiovascular disease risk and improvements to pancreatic beta-cell function. Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus.
publicationForm
publishedIn
type: Periodical
identifier: Print ISSN Type/1175-6349, ISOAbbreviation/Treat Endocrinol, ISSN Linking/1175-6349, Medline Title Abbreviation/Treat Endocrinol, NLM Unique ID/101132977
title: Treatments in endocrinology
publisherLocation: New Zealand
citedMedium: Print
volume: 1
issue: 6
articleDate: 2002
publicationDateText: 2002
language: English
pageString: 411-4
WebLocations
Classifier Url Abstract https://pubmed.ncbi.nlm.nih.gov/15832493/ classification
type: Publishing Model
classifier: Print
classification
type: Chemical
classifier: Hypoglycemic Agents, Thiazolidinediones, Rosiglitazone
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Journal Article, Review
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Wagstaff AJ
forenameInitials: AJ
affiliation: Adis International Inc., Langhorne, Pennsylvania, USA. demail@adis.com
entry
contributor: Goa KL
forenameInitials: KL
Generated Narrative: Practitioner #contributor0
name: Antona J Wagstaff
Generated Narrative: Practitioner #contributor1
name: Karen L Goa
Generated Narrative: ArtifactAssessment #meshHeading0
artifact: Citation 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
content
type: components (if present) include qualifier codings
classifier: Diabetes Mellitus, Type 2
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Hypoglycemic Agents
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Rosiglitazone
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Thiazolidinediones
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
Type Classifier is Major topic Yes